Arteaga C - Search Results

1

Targeting HER1/EGFR: a molecular approach to cancer therapy.

Arteaga C. Arteaga C. Semin Oncol. 2003 Jun;30(3 Suppl 7):3-14. Semin Oncol. 2003. PMID: 12840796 Review.

2

Interference of the IGF system as a strategy to inhibit breast cancer growth.

Arteaga CL. Arteaga CL. Breast Cancer Res Treat. 1992;22(1):101-6. doi: 10.1007/BF01833338. Breast Cancer Res Treat. 1992. PMID: 1421419 Review.

3

p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.

Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ. Arteaga CL, et al. Cancer Res. 1994 Jul 15;54(14):3758-65. Cancer Res. 1994. PMID: 7913407

4

Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA.

Dixit M, Yang JL, Poirier MC, Price JO, Andrews PA, Arteaga CL. Dixit M, et al. Among authors: arteaga cl. J Natl Cancer Inst. 1997 Mar 5;89(5):365-73. doi: 10.1093/jnci/89.5.365. J Natl Cancer Inst. 1997. PMID: 9060958

5

Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL. Lenferink AE, et al. Among authors: arteaga cl. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9609-14. doi: 10.1073/pnas.160564197. Proc Natl Acad Sci U S A. 2000. PMID: 10931950 Free PMC article.

6

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL. Kurokawa H, et al. Among authors: arteaga cl. Cancer Res. 2000 Oct 15;60(20):5887-94. Cancer Res. 2000. PMID: 11059787

7

HER-2/neu (erbB-2) and the cell cycle.

Busse D, Doughty RS, Arteaga CL. Busse D, et al. Among authors: arteaga cl. Semin Oncol. 2000 Dec;27(6 Suppl 11):3-8; discussion 92-100. Semin Oncol. 2000. PMID: 11236025 Review.

8

The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

Arteaga CL. Arteaga CL. J Clin Oncol. 2001 Sep 15;19(18 Suppl):32S-40S. J Clin Oncol. 2001. PMID: 11560969 Review.

9

Tyrosine kinase inhibitors-ZD1839 (Iressa).

Arteaga CL, Johnson DH. Arteaga CL, et al. Curr Opin Oncol. 2001 Nov;13(6):491-8. doi: 10.1097/00001622-200111000-00012. Curr Opin Oncol. 2001. PMID: 11673690 Review.

10

Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance.

Busse D, Yakes FM, Lenferink AE, Arteaga CL. Busse D, et al. Among authors: arteaga cl. Semin Oncol. 2001 Oct;28(5 Suppl 16):47-55. doi: 10.1016/s0093-7754(01)90282-9. Semin Oncol. 2001. PMID: 11706396 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

545 results

Search Page

Filters